Study to Investigate the Performance of Cervical Arthroplasty for the Treatment of Cervical Degenerative Disc Disease

Phase 4

Terminated

Conditions: Cervical Degenerative Disc Disease

Interventions: Device: ACDF
Device: DISCOVER™ Artificial Cervical Disc

Registration Number: NCT00700739

Lead Sponsor: DePuy International

Brief Summary: The purpose of the study is to evaluate the performance of the Discover cervical Artificial disc in the treatment of degenerative disc disease in one level of the cervical spine.

Detailed Description: The protocol underwent 3 amendments, the last of which (02APR2009) changed the study design from a randomized to a non-randomized and non-comparative clinical trial. All of the subjects were enrolled under the randomized design with the exception of the last subject. This study is not applicable per FDAA Title VIII, Section 801 due to the final trial design. However, results are submitted to clinicaltrials.gov due to the majority of study data being collected under a randomized (FDAA Title VIII, Section 801 applicable) trial design

Recruitment & Eligibility

Status: TERMINATED

Sex: All

Target Recruitment: 60

Inclusion Criteria

Male or female subjects, aged between 18 and 65 years inclusive.
Subjects who are able to give voluntary, written informed consent to participate in this clinical investigation and from whom consent has been obtained.
Subjects who, in the opinion of the Clinical Investigator, are able to understand this clinical investigation, co-operate with the investigational procedures and are willing to return to the hospital for all the required post-operative follow-ups.
Objective evidence of cervical disc disease in one vertebral level between C3-C7 defined as one or more of the following:
- Shoulder and/or arm pain in a radicular distribution resulting from herniated disc or bony osteophytes (Consistent w diagnostic imaging including Axial CT, CT Myelogram, MRI and/or plain films)
- Subjects with myeloradiculopathy resulting from mild spinal cord compression and nerve root impingement
Unresponsive to documented non-surgical management for ≥ 6 weeks and/or presents with progressive symptoms of nerve root or spinal cord compression in the face of continued non-surgical management (e.g., physical therapy, medication therapy, corticosteroid injections, etc.)
Minimum Neck Disability Index score of ≥30 % (15/50 points)

Exclusion Criteria

Subjects who, in the opinion of the Clinical Investigator, have an existing condition that would compromise their participation and follow-up in this clinical investigation.
Subjects who are pregnant, lactating or wishes to become pregnant within the duration of the study.
Subjects who are known drug or alcohol abusers or with psychological disorders that could affect follow-up care or treatment outcomes.
Subjects who have participated in a clinical investigation with an investigational product in the last 30 days.
Subjects who are currently involved in any injury litigation claims.
Subjects with significant degeneration at more than one cervical level (e.g. DISH, ankylosing spondylitis, congenital abnormality, rheumatoid arthritis)
Subjects who have had any prior surgery at the level to be treated (subjects with a prior Laminotomy at the level to be treated may be included in the study)
Subjects who have marked cervical instability on lateral or flexion/extension x-rays defined as translation ≥3mm and/or ≥11 degrees of rotational difference to either adjacent level
Subjects who have presence of systemic infection or infection at the site of surgery
Subjects who have been diagnosed with malignancy
Subjects who have been diagnosed with a condition or require postoperative medication(s) that may interfere with bony/soft tissue healing
Subjects who have been diagnosed with Osteoporosis, Osteopenia, other metabolic bone disease or endocrine disorder known to affect osteogenesis.
Subjects with pre-existing neurological abnormalities other than deficits produced from the spinal lesion (e.g., MS, Parkinson's, CVA, diabetic neuropathy, peripheral neuropathy).
Subjects with morbid obesity defined as a BMI of ≥40, or more than 100 lbs (45.4kg) over ideal weight.
Subjects with any known allergy to titanium metal, polyethylene, metal alloy or carbon fibre reinforced polymer
Subjects who have had prior fusion surgery at any level(s) (C1-T1)
Subjects with kyphosis >-15 degrees evaluated using the Cobb angle measurement
Subjects with Significant cervical degenerative disease characterized by bridging anterior osteophytes, significant loss of disc space height (3mm or less), sclerotic facets, large posterior osteophytes, autofusion of other cervical levels, and degenerative retrolisthesis. Spinal diseases such as DISH, ankylosing spondylitis, congenital abnormality, and rheumatoid arthritis, should also be excluded
Subjects undergoing treatment with a bone growth stimulator, which cannot be discontinued prior to enrollment in the study.
Significant kyphotic deformity or significant reversal of lordosis.

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Anterior Cervical Discectomy and Fusion (ACDF)	ACDF	Anterior Cervical Discectomy and Fusion with Cervical CFRP I/F CAGE® and SLIM LOC(R) Anterior Cervical Plate System with allograft
Cervical Total Disc Replacement	DISCOVER™ Artificial Cervical Disc	DISCOVER™ Artificial Cervical Disc

Primary Outcome Measures

Name	Time	Method
Overall Patient Success	12 months	Overall success was a composite endpoint determined by the following clinical outcome measures: 1. Neck Disability Index ≥ 15-point improvement from baseline to 12 months post-operative, 2. No new clinically significant permanent abnormalities in neurological function (i.e. motor strength, nerve root tension signs, sensory and reflex signs) from baseline to 12 months post-operative, 3. No subsequent secondary surgical interventions (SSI) at the index level, and 4. No device-related serious events (dSAE) from intra-operative through 12-months post-operative. Please note that these time periods were intended to be from baseline to 24 months post-operative, but since the study was terminated early the 12 month time periods were utilized.

Secondary Outcome Measures

Name	Time	Method
Change in Visual Analogue Scale (VAS) Right Arm Pain From Pre-treatment to 12 Months.	12 Months	The visual analogue scale (VAS) pain score asks the subject to place a vertical mark on a horizontal line (that is approximately 10 cm long) with 'No Pain' (score of 0= 0 cm) listed on the left and 'Very severe pain' (score of 100= 10 cm) labeled on the right. The subject is instructed to indicate the amount of pain they feel in their right arm.
Change in Visual Analogue Scale (VAS) Right Shoulder Pain From Pre-treatment to 12 Months.	12 Months	The visual analogue scale (VAS) pain score asks the subject to place a vertical mark on a horizontal line (that is approximately 10 cm long) with 'No Pain' (score of 0 = 0 cm) listed on the left and 'Very severe pain' (score of 100 = 10 cm) labeled on the right. The subject is instructed to indicate the amount of pain they feel in their right shoulder.
Change in Visual Analogue Scale (VAS) Left Shoulder Pain From Pre-treatment to 12 Months.	12 Months	The visual analogue scale (VAS) pain score asks the subject to place a vertical mark on a horizontal line (that is approximately 10 cm long) with 'No Pain' (score of 0 = 0 cm) listed on the left and 'Very severe pain' (score of 10 = 10 cm) labeled on the right. The subject is instructed to indicate the amount of pain they feel in their left shoulder.
Change in Mental Component Summary Quality of Life Measure Assessed by Short Form SF-36 From Pre-treatment to 12 Months	12 months	The 36-item Short Form Health Survey (SF-36) is a patient reported outcome survey that evaluates functional health and well-being. The survey is converted into 2 summary measures that are scored from 0 to 100 (where 100 indicates the highest level of health) - the Physical Component Score (PCS-36) and Mental Component Score (MCS-36)
Adjacent Level Degeneration Measured Radiographically at 24 Months	24 months	Adjacent Level Degeneration is evaluated using a point system that assigns numerical scores to severity of Height Loss, Anterior Osteophytes, and Endplate Sclerosis; and then grades into one of the following five categories: None, Mild, Moderate, Severe, or NA.
Change in Visual Analogue Scale (VAS) Neck Pain From Pre-treatment to 12 Months	12 months	The visual analogue scale (VAS) pain score asks the subject to place a vertical mark on a horizontal line (that is approximately 10 cm long) with 'No Pain' (score of 0 = 0 cm) listed on the left and 'Very severe pain' (score of 100 = 10 cm) labeled on the right. The subject is instructed to indicate the amount of pain they feel in their neck.
Change in Visual Analogue Scale (VAS) Left Arm Pain From Pre-treatment to 12 Months.	12 Months	The visual analogue scale (VAS) pain score asks the subject to place a vertical mark on a horizontal line (that is approximately 10 cm long) with 'No Pain' (score of 0 = 0 cm) listed on the left and 'Very severe pain' (score of 100 = 10 cm) labeled on the right. The subject is instructed to indicate the amount of pain they feel in their left arm.
Foraminal Height Measured Radiographically at 24 Months	24 months	Foraminal height is the maximum vertical distance, measured in millimeters (mm), between the inferior surface of the superior pedicle and superior surface of the inferior pedicle. These measurements are obtained via magnetic resonance imaging (MRI).
Change in Physical Component Summary Quality of Life Measure Assessed by Short Form SF-36 From Pre-treatment to 12 Months	12 months	The 36-item Short Form Health Survey (SF-36) is a patient reported outcome survey that evaluates functional health and well-being. The survey is converted into 2 summary measures that are scored from 0 to 100 (where 100 indicates the highest level of health) - the Physical Component Score (PCS-36) and Mental Component Score (MCS-36)
Cervical Range of Motion Measured Radiographically at 6 Months	6 months	Cervical range of motion measures the angle, in degrees, between the inferior endplate of C2 to the inferior endplate of C7 on flexion-extension radiographs.
Device Related Adverse Events	Intra-operatively to 24 months post-operative	The proportion of subjects with device related adverse events as reported throughout the duration of the study.
Sagittal Angulation, Also Known as Global Lordosis, Measured Radiographically at 6 Months	6 months	Sagittal Angulation is a measure of the angle formed between the inferior endplate of the C2 vertebrae and the corresponding inferior endplate of vertebrae C7 of the spine, measured in degrees, from a side (sagittal) view.
Maintenance of Disc Height Measured Radiographically at 6 Months	6 months	Maintenance of disc height is measured at the index and adjacent levels to determine the effect of the treatment on restoration or maintenance of the disc height. Initial post-operative disc height is compared with subsequent post-operative visits (i.e. 6 months) to evaluate the maintenance of disc height. The height is measured in millimeters (mm).
Change in Function Assessed by Neck Disability Index Improvement From Pre-treatment to 12 Months	12 months	The neck disability index (NDI) is a validated, disease specific, self-administrated questionnaire for assessing pain intensity and function in patients with neck pain on a scale from 0 to 100. A lower score is a better result (i.e. less severe pain and/or better function). The proportion of patients with an improved score (lower) of 15 points or more was the analysis variable.
Work Status Assessed at 12 Months	12 months	The proportion of subjects with unrestricted work status (compared to subjects not working or with restricted work status) is reported at the 12 month follow-up interval.

Trial Locations

Locations (8): La Paz Hospital
🇪🇸
Madrid, Spain
Westmead Private Hospital
🇦🇺
Sydney, New South Wales, Australia
Calvary Hospital
🇦🇺
Tasmania, Australia
Divisione di Neurochirurgia
🇮🇹
Rome, Italy
Klinikum Neustadt
🇩🇪
Neustadt, Holstein, Germany
Island Hospital
🇲🇾
Penang, Malaysia
Elisabeth Ziekenhuis
🇳🇱
Tilburg, Netherlands
Hope Hospital
🇬🇧
Manchester, Lancashire, United Kingdom